GOG

IGU 2022 Global Wholesale Gas Price Survey Report

Retrieved on: 
Wednesday, October 5, 2022
International Gas Union, Pressure, OPE, Time, Risk, Share, Efficiency, Growth, Conference, Annual, MMBTU, GOG, WGC, COVID-19, Multimedia, Oil, Henry Hub, Environmental and Energy Study Institute, Oxford Institute for Energy Studies, Hydrogen, IGU, View, Renewable energy, Natural gas, Publishing, LNG

LONDON, Oct. 5, 2022 /PRNewswire/ - The International Gas Union (IGU) today releases its 2022 Wholesale Gas Price Survey Report.

Key Points: 
  • LONDON, Oct. 5, 2022 /PRNewswire/ - The International Gas Union (IGU) today releases its 2022 Wholesale Gas Price Survey Report.
  • The Annual IGU Wholesale Gas Price Survey report was launched in 2005.
  • It is a unique global database on the evolution of gas markets, changes in gas price formation mechanisms, and wholesale gas prices.
  • The IGU organises flagship international gas conferences, including World LNG Congress, the World Gas Conference (WGC), and International Gas Research Conference www.igu.org .

IGU 2022 Global Wholesale Gas Price Survey Report

Retrieved on: 
Wednesday, October 5, 2022
International Gas Union, Pressure, OPE, Time, Communes of Burundi, Risk, Share, Efficiency, Growth, Conference, Annual, MMBTU, GOG, WGC, COVID-19, Oil, Henry Hub, Environmental and Energy Study Institute, Oxford Institute for Energy Studies, Hydrogen, IGU, Renewable energy, Natural gas, LNG

LONDON, Oct. 5, 2022 /PRNewswire/ -- The International Gas Union (IGU) today releases its 2022 Wholesale Gas Price Survey Report. The survey is the [14th] to be undertaken in a series that began in 2005.

Key Points: 
  • LONDON, Oct. 5, 2022 /PRNewswire/ -- The International Gas Union (IGU) today releases its 2022 Wholesale Gas Price Survey Report.
  • The Annual IGU Wholesale Gas Price Survey report was launched in 2005.
  • It is a unique global database on the evolution of gas markets, changes in gas price formation mechanisms, and wholesale gas prices.
  • The IGU organises flagship international gas conferences, including World LNG Congress, the World Gas Conference (WGC), and International Gas Research Conference www.igu.org .

Genelux Corporation Initiates a Pivotal Phase 3 Trial, Evaluating Olvi-Vec for the treatment of Platinum-Resistant/Refractory Ovarian Cancer

Retrieved on: 
Wednesday, September 21, 2022
Safety, Bevacizumab, Memory, Engineering, Woman, CI, Recurrence, Ovarian cancer, Vaccinia, Vagina, Company, Medicine, United, Clinical Ovarian Cancer & Other Gynecologic Malignancies, GOG, SEER, Immunotherapy, Survival, Vulva, Patient, Cancer, NCI, Clinical Oncology, CEO, Urogenital pelvic malignancy, ORR, Progression-free survival, Uterus, Neoplasm, Method, Death, Research, Abdominal pain, GLOBE, DNA, Disease, RECIST, Immunogenic cell death, Pharmaceutical industry, Birth control, Vaccine, Genelux Corporation, Gynecologic Oncology (journal), Epidemiology

Initiating the OnPrime trial represents a major milestone for Genelux, saidThomas D. Zindrick, President and CEO, Genelux.

Key Points: 
  • Initiating the OnPrime trial represents a major milestone for Genelux, saidThomas D. Zindrick, President and CEO, Genelux.
  • Our goal in Phase 3 is to replicate these positive results and transform the treatment paradigm for this particularly difficult-to-treat cancer.
  • We look forward to progressing our study and sharing updates on the Olvi-Vec clinical development program.
  • Virus-mediated oncolysis results in immunogenic cell death and triggers immune activation and memory for long-term immunotherapy against cancer.

CanariaBio Announces Milestone achievement of 50% patient enrollment in its Phase III FLORA-5 clinical study of its lead product oregovomab in front-line advanced ovarian cancer treatment

Retrieved on: 
Thursday, June 30, 2022
Death, Patient, Biotechnology, HER2/neu, MUC1, Gynaecology, Trial of the century, Immunization, Cancer, Immunoglobulin G, Terminology, GOG, PSA, Risk, Overalls, Immunotherapy, Toxicity, Antibody, Oregovomab, Survival, Paclitaxel, FRCPC, Leadership, Safety, MH, Carboplatin, Drug combination, Ovarian cancer, Cancer immunology, Pharmaceutical industry

For this ongoing Phase-III study, the last Independent Data Safety Monitoring Board (IDSMB) meeting held in March 2022 identified no safety concerns and IDSMB recommended to continue the study without modifications.

Key Points: 
  • For this ongoing Phase-III study, the last Independent Data Safety Monitoring Board (IDSMB) meeting held in March 2022 identified no safety concerns and IDSMB recommended to continue the study without modifications.
  • Indirect immunization with oregovomab interacts with immune modulating properties of infused paclitaxel and carboplatin resulting in synergistic clinical benefit as observed in a phase 2 trial.
  • Clinical and translational results were published in Gynecology Oncology 2020 156:523-529) and Cancer Immunology and Immunotherapy 2020 69: 383-397, respectively.
  • CanariaBio Inc. is a Korean biopharmaceutical company focused on the development and commercialization of immunotherapies for cancer.

CanariaBio Announces Milestone achievement of 50% patient enrollment in its Phase III FLORA-5 clinical study of its lead product oregovomab in front-line advanced ovarian cancer treatment

Retrieved on: 
Thursday, June 30, 2022
Death, View, Patient, Biotechnology, HER2/neu, MUC1, Gynaecology, Trial of the century, Immunization, Cancer, Multimedia, Immunoglobulin G, Terminology, GOG, PSA, Risk, Overalls, Immunotherapy, Toxicity, Antibody, Oregovomab, Survival, Paclitaxel, FRCPC, Leadership, Safety, MH, Carboplatin, Drug combination, Ovarian cancer, Cancer immunology, Pharmaceutical industry

For this ongoing Phase-III study, the last Independent Data Safety Monitoring Board (IDSMB) meeting held in March 2022 identified no safety concerns and IDSMB recommended to continue the study without modifications.

Key Points: 
  • For this ongoing Phase-III study, the last Independent Data Safety Monitoring Board (IDSMB) meeting held in March 2022 identified no safety concerns and IDSMB recommended to continue the study without modifications.
  • Indirect immunization with oregovomab interacts with immune modulating properties of infused paclitaxel and carboplatin resulting in synergistic clinical benefit as observed in a phase 2 trial.
  • Clinical and translational results were published in Gynecology Oncology 2020 156:523-529) and Cancer Immunology and Immunotherapy 2020 69: 383-397, respectively.
  • CanariaBio Inc. is a Korean biopharmaceutical company focused on the development and commercialization of immunotherapies for cancer.

Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

Retrieved on: 
Tuesday, June 21, 2022
Time, Immunity, NK, RNA, FDA, Gynecologic Oncology Group, Safety, III, Tumor microenvironment, IV, Company, Recurrence, U.S. Securities and Exchange Commission, Cancer, Research, Private Securities Litigation Reform Act, EOC, Work, DSMB, Cell proliferation, Progression-free survival, DNA, Interim, GLOBE, Surface epithelial-stromal tumor, NASDAQ, Fast track (FDA), Phase, Ovarian cancer, Paclitaxel, Peritoneal cavity, Partnership, Data monitoring committee, CRS, Carboplatin, Patient, Toxic leukoencephalopathy, Neoplasm, Diagnosis, PFS, Malignancy, GOG, Woman, Immunotherapy, Risk, Pharmaceutical industry, Medical device, Vaccine

LAWRENCEVILLE, N.J., June 21, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that following a pre-planned interim safety review of 87 as treated patients (46 patients in the experimental arm and 41 patients in the control arm) randomized in the Phase I/II OVATION 2 Study with GEN-1 in advanced (Stage III/IV) ovarian cancer, the Data Safety Monitoring Board (DSMB) has unanimously recommended that the OVATION 2 Study continue treating patients with the dose of 100 mg/m2. The DSMB also determined that safety is satisfactory with an acceptable risk/benefit, and that weekly doses of GEN-1 were well tolerated during a course of treatment that is given over six months in combination with standard neoadjuvant chemotherapy. No dose-limiting toxicities were reported.

Key Points: 
  • The OVATION 2 Study combines GEN-1, the Company's IL-12 gene-mediated immunotherapy, with standard-of-care neoadjuvant chemotherapy (NACT) in patients newly diagnosed with Stage III/IV ovarian cancer.
  • NACT is designed to shrink the cancer as much as possible for optimal surgical removal after three cycles of chemotherapy.
  • Following NACT, patients undergo interval debulking surgery, followed by three additional cycles of chemotherapy to treat any residual tumor.
  • The Company also announced that more than 87% of the projected 110 patients have been enrolled in the OVATION 2 Study.

Celsion Corporation Highlights Pipeline Progress in Its Lead Development Candidates

Retrieved on: 
Tuesday, May 10, 2022
COVID-19, COVID 19, Bevacizumab, Private Securities Litigation Reform Act, Immunoglobulin G, Severe acute respiratory syndrome coronavirus 2, Failure, NASDAQ, Pharmacokinetics, GLOBE, Toxicity, Neoplasm, Nanoparticle, Time, GOG, Immunotherapy, Patient, Immunity, COVID, Partnership, Program, FDA, Cancer, Doxorubicin, DNA, Ovarian cancer, Gynecologic Oncology Group, Primate, Abdominal cavity, Vaccine, Congress, U.S. Securities and Exchange Commission, Vaccination, Research, Risk, Phase

LAWRENCEVILLE, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today provided an update on the progress made in the Company’s two lead development programs.

Key Points: 
  • LAWRENCEVILLE, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation(NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today provided an update on the progress made in the Companys two lead development programs.
  • We continue to make important progress in both of our lead development programs, and I am very pleased by the encouraging results to date, said Michael H. Tardugno, chairman, president and chief executive officer of Celsion.
  • This proof-of-concept data is comparing favorably to commercial vaccines in mouse models with this data recently reported at the World Vaccine Congress.
  • Celsions wholly owned subsidiary, Celsion GmbH, is managing ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is under investigator-sponsored development for several cancer indications.

Clovis Oncology Announces First Quarter 2022 Operating Results and Provides Update on Clinical Development Programs

Retrieved on: 
Wednesday, May 4, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, ASCO, Clovis Oncology, Sixth Street Partners, Population, PFS, Radiation, Maintenance, Woman, NASDAQ, LLC, Company, Research, GOG, Patient, ATHENA, Program, Nivolumab, Database administrator, SSP, CEO, ITT, Pharmaceutical industry, Medical imaging, Health insurance, Rucaparib

Clovis Oncology , Inc. (NASDAQ:CLVS) reported financial results for the quarter ended March 31, 2022, and provided an update on the Companys clinical development programs and regulatory and commercial outlook.

Key Points: 
  • Clovis Oncology , Inc. (NASDAQ:CLVS) reported financial results for the quarter ended March 31, 2022, and provided an update on the Companys clinical development programs and regulatory and commercial outlook.
  • Clovis expects research and development expenses in the full year 2022 to be comparable to 2021.
  • Net cash used in operating activities was $58.5 million for Q1 2022, down 5% from the $61.9 million reported in Q1 2021.
  • Clovis will hold a conference call this morning, May 4, at 8:30 am ET, to discuss Q1 2022 results and provide an update on the Companys clinical development programs and regulatory and commercial outlook.

Relacorilant Plus Nab-Paclitaxel Extends Survival in Women with Recurrent, Platinum-resistant Ovarian Cancer

Retrieved on: 
Wednesday, March 30, 2022
Risk, Recurrence, University, Safety, Population, NASDAQ, Sale, See, Death, HIV disease progression rates, Board, Overalls, Corcept Therapeutics, Doctor of Pharmacy, Survival, Ovarian cancer, Woman, Neoplasm, Patient, Associate, CORT, OS, Â, PFS, MD, Dor, GLOBE, Paralympic record progression track cycling – Women's 1 km time trial, Gynecologic Oncology Group, GOG, Arm, Lists of diseases, FDA, Disease, Pharmaceutical industry

As is typical of late-stage clinical trials, such women will not be enrolled in Corcepts upcoming Phase 3 trial.

Key Points: 
  • As is typical of late-stage clinical trials, such women will not be enrolled in Corcepts upcoming Phase 3 trial.
  • In this large, randomized study, women with recurrent, platinum-resistant ovarian cancer who were administered relacorilant at the time they received nab-paclitaxel exhibited meaningful improvements in progression free survival, duration of response and overall survival without increased side effects compared to women who received nab-paclitaxel alone.
  • No approved therapy has been shown to significantly extend survival compared to standard chemotherapy in women with platinum-resistant ovarian cancer.
  • Fourteen additional women in the intermittent arm and nine additional women in the comparator arm are expected to contribute to the final overall survival results.

Novocure Announces Favorable Recommendation to Continue the Phase 3 Pivotal INNOVATE-3 Study of Tumor Treating Fields in Ovarian Cancer

Retrieved on: 
Wednesday, March 23, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Fundamental, Recurrence, LinkedIn, Glioblastoma, Population, Large-cell lung carcinoma, NASDAQ, Private Securities Litigation Reform Act, European Society of Gynaecological Oncology, Diagnosis, European Network for Health Technology Assessment, Particle-size distribution, Death, Forward-looking statement, Toxicity, Physician, Skin, Adult, Survival, Neoplasm, Alternating electric field therapy, Ovarian cancer, Progression-free survival, Woman, Standard of care, Incidence, Cancer, Quality of life, DMC, Safety, Paclitaxel, Mesothelioma, Twitter, U.S. Securities and Exchange Commission, Stomach, Liver cancer, COVID-19, GOG, Annual report, Pancreatic cancer, Patient, Disease, Prognosis, Pharmaceutical industry, Medical imaging

An independent data monitoring committee (DMC) reviewed the safety data for all platinum-resistant ovarian cancer patients enrolled on the trial.

Key Points: 
  • An independent data monitoring committee (DMC) reviewed the safety data for all platinum-resistant ovarian cancer patients enrolled on the trial.
  • The INNOVATE-3 study is designed to evaluate the safety and effectiveness of TTFields together with paclitaxel in patients with platinum-resistant ovarian cancer.
  • In the U.S., ovarian cancer ranks fifth in cancer deaths among women, with approximately 24,000 women diagnosed each year.
  • Novocure has ongoing or completed clinical studies investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.